Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Can Fite BiopharmaCANF +0.31%52 Net-Net Working Capital is $3.53 as of Dec. 2025. GuruFocus rates CANF with a GF Score™ of 52/100 and a GF Value™ of $1.25 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 860 Biotechnology companies, Can Fite Biopharma ranks better than 92.91% on this metric.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
Can Fite Biopharma's Net-Net Working Capital for the quarter that ended in Dec. 2025 was $3.53.
The industry rank for Can Fite Biopharma's Net-Net Working Capital or its related term are showing as below:
CANF's Price-to-Net-Net-Working-Capital is ranked better than 92.91% of 860
companies
in the Biotechnology industry
Industry Median: 5.455
vs CANF: 0.94
Can Fite Biopharma (AMEX:CANF) Net-Net Working Capital Explanation
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.
Can Fite Biopharma Net-Net Working Capital Related Terms
Can Fite Biopharma Net-Net Working Capital Historical Data
* Premium members only.
The historical data trend for Can Fite Biopharma's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CANF vs VRTX, REGN, ALNY: Net-Net Working Capital Comparison
For the Biotechnology subindustry, Can Fite Biopharma's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Can Fite Biopharma Price-to-Net-Net-Working-Capital vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Can Fite Biopharma's Price-to-Net-Net-Working-Capital distribution charts can be found below:
* The bar in red indicates where Can Fite Biopharma's Price-to-Net-Net-Working-Capital falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
What does a Net-Net Working Capital of $3.53 mean?
Can Fite Biopharma (CANF) has a Net-Net Working Capital of $3.53 as of Dec. 2025. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Can Fite Biopharma According to the industry distribution chart, Can Fite Biopharma ranks #61 out of 860 companies in the Biotechnology industry, placing it in the top 7.1%.
Is Can Fite Biopharma's Net-Net Working Capital too high?
Can Fite Biopharma's current Net-Net Working Capital is $3.53. The Biotechnology industry median Net-Net Working Capital is 5.46. Can Fite Biopharma's value of $3.53 is 35.3% below this industry median. Based on the distribution chart, Can Fite Biopharma ranks #61 out of 860 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Can Fite Biopharma has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Can Fite Biopharma's Net-Net Working Capital compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Can Fite Biopharma ranks #61 out of 860 companies for Net-Net Working Capital. This places Can Fite Biopharma in the top 7% of its industry — outperforming the majority of peers. The industry median Net-Net Working Capital is 5.46. Can Fite Biopharma's value of $3.53 is 35.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.46, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Can Fite Biopharma's current Net-Net Working Capital of $3.53 is 35.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Can Fite Biopharma For the Biotechnology industry, the median Net-Net Working Capital is 5.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Can Fite Biopharma's current Net-Net Working Capital is $3.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Can Fite Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Can Fite Biopharma (CANF) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.25, compared to a current price of $3.26 — trading 160.8% above its estimated fair value. The current Net-Net Working Capital is $3.53 and 35.3% below the Biotechnology industry median of 5.46. Can Fite Biopharma's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Can Fite Biopharma (CANF), the current Net-Net Working Capital is $3.53 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Can Fite Biopharma (CANF) Overvalued in 2026?
Based on GuruFocus' analysis, Can Fite Biopharma stock appears to be overvalued.
The current stock price of $3.26 is trading 160.8% above its estimated GF Value™ of $1.25.
GuruFocus considers Can Fite Biopharma to be Significantly Overvalued.
Key valuation signals for CANF:
Net-Net Working Capital: $3.53
GF Value™: $1.25 vs. price of $3.26 (160.8% above fair value)
Industry Position: 35.3% below the Biotechnology median (#61 of 860)
No single metric tells the full story. See the CANF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
52GF Score
Get the complete analysis for CANF
Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CANF has been successfully added to your 
